Exelixis Reports Favorable Trial Results for Kidney Cancer Drug
26 September 2015 - 9:45AM
Dow Jones News
By Josh Beckerman
Exelixis Inc. provided updated Phase 3 trial results for its
kidney cancer drug cabozantinib, which "significantly improved
progression-free survival" compared with Novartis AG's everolimus,
or Afinitor.
Exelixis said in July that cabozantinib met its primary endpoint
in the trial, increasing survival.
The biopharmaceutical company said Friday that "treatment with
cabozantinib resulted in a strong trend towards improving overall
survival."
Results were favorable in the full study population for the
primary endpoint analysis as well as a subgroup of patients who had
received sunitinb as their only prior VEGF receptor tyrosine kinase
inhibitor, the company said.
Shares of Exelixis were up 15% to $6.79 in after-hours
trading.
Cabozantinib was granted fast-track designation by the Food and
Drug Administration in April, a status that can help speed approval
for drugs and vaccines that address serious conditions and unmet
medical needs.
Exelixis said it is on track for a New Drug Application filing
in the U.S. by the end of 2015, and expects a European filing in
early 2016.
Write to Josh Beckerman at josh.beckerman@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 25, 2015 19:30 ET (23:30 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024